Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.

ABSTRACT: PURPOSE:In this study, a therapeutic drug monitoring (TDM) of erlotinib in pancreatic cancer patients was performed over 50 weeks to reveal possible alterations in erlotinib plasma concentrations. Additionally, a physiologically based pharmacokinetic (PBPK) model was created to assess such variations in silico. METHODS:Patients with advanced pancreatic cancer received a chemotherapeutic combination of 100 mg erlotinib q.d., 500-900 mg capecitabine b.d. and 5 mg/kg bevacizumab q.2wks. Samples were analyzed by HPLC and the results were compared to a PBPK model, built with the software GastroPlus™ and based on calculated and literature data. RESULTS:The erlotinib plasma concentrations did not show any accumulation, but displayed a high inter-patient variability over the whole investigated per

SUBMITTER: Gruber A 

PROVIDER: S-EPMC5854746 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature